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Abstract
Because our beliefs regarding our individuality, autonomy, and personhood are intimately bound up with our brains,
there is a public fascination with cerebral organoids, the “mini-brain,” the “brain in a dish”. At the same time, the
ethical issues around organoids are only now being explored. What are the prospects of using human cerebral
organoids to better understand, treat, or prevent dementia? Will human organoids represent an improvement on the
current, less-than-satisfactory, animal models? When considering these questions, two major issues arise. One is the
general challenge associated with using any stem cell–generated preparation for in vitro modelling (challenges amplified
when using organoids compared with simpler cell culture systems). The other relates to complexities associated with
defining and understanding what we mean by the term “dementia.” We discuss 10 puzzles, issues, and stumbling blocks
to watch for in the quest to model “dementia in a dish.”
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Introduction
Cerebral organoids (Fig. 1), or “mini-brains” as they are
commonly referred to, are three-dimensional tissue structures that are generated in vitro (often from pluripotent
stem cells) (Pașca 2018), containing different cell types
of the brain, and representing the anatomical structures of
the brain (Fig. 2). Organoids are used for disease modelling for dementia (summarized in Table 1); however,
there are a number of important considerations. We outline the 10 big questions that impinge on the design and
interpretation of experiments using cerebral organoids
from dementia patients.

Question 1: How Do We Define
Dementia? What Is Its True Burden?
Dementia is a syndrome that is caused by different neurodegenerative diseases, including Alzheimer’s disease,

Parkinson’s disease, Huntington’s disease (Silverberg
and others 2018). Few people in medical research underestimate the prevalence of the disease on which they
work; meanwhile prevalence and incidence rate estimates are affected by comorbidity and misdiagnoses
(van der Flier and Scheltens 2005). Coexisting uneasily
with this is a public fear of losing one’s mind through
dementia, of alarming (or alarmist) predictions of runaway personal costs due to the basic loss of control and
dignity that is central to dementia, and the economic
costs confronting the health and aged care systems. Accurate figures are necessary so the health care
system can estimate the burden of disease and plan for
the personal and institutional cost of treatment. Accurate
figures are also essential to determine if populationbased interventions are effective.
Dementia describes a syndrome where there is progressive loss of cognitive skills over time, sufficient to
interfere with independent living. This can be due to one
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of several underlying causes, or to more than one cause
acting together. During the normal process of ageing,
many people lose cognitive skills, but for the majority
this is not sufficient to cause more than inconvenience or
anxiety. By contrast, by the age of 90, 28% of men and
45% of women develop dementia, according to a population study in the United States (Corrada and others 2008).
Similar estimates come from other high-income countries, but it is not clear if the same applies in middleincome countries that now are achieving an ageing profile
similar to the United States or Australia, such as China
and India.
We also do not have accurate information on whether
the age-adjusted incidence of dementia is genuinely
decreasing when compared to 20 years ago (Satizabal and
others 2016; Seblova and others 2018; Wu and others
2017). Addressing this problem is vitally important for
obtaining accurate epidemiological estimates of incidence, progression, and the impact of care. Drift in diagnostic criteria over time (Jack and others 2018) has made
such comparisons difficult. The way in which the financial burden of care is allocated by disease also will affect
the diagnoses that are offered (McPhail 2016). Defining
dementia and its burden is important when considering
using organoids as a disease model; if we are not able to
define or accurately diagnose disease we could be studying cells from people that do not represent dementia
patients.

Question 2: What Is the True
Etiology of Dementia?
Most research begins with a clinical assessment to
determine whether a patient has dementia. Experienced
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geriatricians, psychiatrists, neurologists, and psychologists can distinguish dementia from other mental illness
or delirium. However, differential diagnosis between
the four common dementia etiologies is challenging.
Alzheimer dementia (AD), vascular dementia (VD),
dementia with Lewy Bodies (DLB), and frontotemporal
lobar dementia (FTLD) share many clinical features, but
different etiologies, and relying solely on clinical assessment has limitations if all four are lumped together as
“dementia.” It is particularly important to separate VD
from the other causes of dementia, as it is often preventable, has a major environmental component, and does
not “progress” as Alzheimer disease does.
Furthermore, several age-related neurodegenerative
diseases can coexist in the elderly brain (Boyle and others
2018) and hence use of biomarkers for phenotyping will
be limited unless all four major causes of dementia are
considered. This rarely happens at present. Stem cells
generated from research participants (invariably labelled
with a single diagnosis) could have multiple background
neuropathologies, potentially compromising both “disease” and “control” cell lines.
Given that a person with dementia may have a biomarker pattern indicating more than one etiology, the
challenging question then becomes how to best define
the “prime mover.” For AD, combining genetics (the
presence of APOE4), biomarkers (amyloid-beta fragment ratios in blood and/or cerebral spinal fluid), and
imaging (amyloid as seen using positron emission
tomography) is diagnostic (Jack and others 2018;
Villemagne and others 2018). Similar multidisciplinary
approaches are being developed to diagnose DLB and
FTLD, incorporating genetic risk, biomarker assessment, and imaging (Meeter and others 2017). The
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Figure 1. The experimental paradigm using cerebral organoids to investigate Alzheimer’s disease. (A) Alzheimer’s disease
(AD) is the most prevalent form of dementia and is characterized by neuronal cell death to the cortex and hippocampus
of the brain resulting in impaired memory, cognition, and behavior. The underlying molecular mechanisms that result in
neurodegeneration remain to be defined, with patient-derived induced pluripotent stem cells (iPSCs) offering a biologically
relevant model to better understand the biological basis of AD. The AD brain shows a reduced volume due to the loss of
synapses and neurons. (B) During normal development pluripotent stem cells differentiate into multiple cell types of the body,
including cells from the three germ layers, the ectoderm, mesoderm, and endoderm. Terminally differentiated cells, such as
skin cells, can be reprogrammed to generate iPSCs that have the capacity to differentiate into multiple cell types of the body.
(C) To model AD in a dish, patients donate cells (such as skin cells) that are reprogrammed into iPSCs. The iPSCs can then be
differentiated into neurons or other cell types. The use of AD patient–derived iPSCs allows researchers to generate cells of a
specific lineage, including neurons and glial cells, to characterize disease phenotypes that may be a result of the patient’s genetic
makeup and to develop new therapeutics via drug screening. (D) Cerebral organoids are three-dimensional stem cell cultures
that have the advantage over traditional two-dimensional culture approaches as they allow the stem cells to self-organize
into structures, form signaling networks and develop cell-cell interactions that better mimic in vivo neurodevelopment. These
three-dimensional culture systems allow us to better model and further interrogate the roles that different neural and glial cell
types play in neurodegeneration. The cerebral organoids contain a mixture of neural cell types that represent the anatomical
structure of the brain.

diagnosis of VD relies primarily on neuroimaging
(using magnetic resonance imaging) to reveal either
macro- or microvascular disease. Given the advanced
state of these technologies, any stem cell–related modelling approach must start by demanding a high-quality
diagnostic workup of the persons providing the donor
cells. For data from organoids to be meaningful, we
need to be able to label each with an accurate history,
including types of dementia and staging.

Question 3: Comorbidity and Why Is
Age the Biggest Risk Factor?
Most people with dementia are elderly. Many elderly
people have comorbidities, such as hypertension, coronary artery disease, depression, or diabetes. Vascular risk
factors and related conditions that develop in later life,
including cardiovascular disease, diabetes, hypertension,
and stroke, are all associated with an increased risk of
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Figure 2. Generalized schematic of cerebral organoid differentiation based on Lancaster and Knoblich (2014). (A) Small
molecule inhibitors are added to human pluripotent stem cells to drive differentiation toward a cortical phenotype. Scale
bar = 200 µm. (B) Following neural induction, neural rossettes are harvested for three-dimensional culture as neurospheres.
Scale bar = 200 µm. (C) Cortical neurospheres are cultured in suspension to allow for maturation and expansion. Following
2 weeks, neurospheres are maintained for longer times to allow for further self-organization and differentiation. Cortical
neurospheres self-organize into distinct structures. Neural rosettes observed in vitro during cerebral organoid culture
(highlighted in the rectangle) represent the neural tube formation in vivo during human neurodevelopment. Scale bar = 200 µm.
(D) Cerebral organoids are maintained for long-term culture allowing for neural differentiation that recapitulates human brain
development, and continue to grow in size. Scale bar = 200 µm. Cerebral organoids can be cryosectioned and characterized by
immunocytochemistry, using antibodies directed at specific neuronal and glial markers to show the heterogeneous populations of
cells contained within an individual organoid. A representative example of a cerebral organoid derived from a healthy individual
shows the nuclear stain, Hoechst, blue (E); the mature neuronal marker microtubule associated protein 2 (MAP2), green (F); the
astrocyte marker glial fibrillary acidic protein (GFAP), red (G); the merged overlay (H; scale bar = 25 µm); and a magnified image
to show the mix of neurons and astrocytes in the organoid (I; scale bar = 50 µm).

dementia (Breteler 2000). Furthermore, it is not clear
whether different morbidities combine in an additive or
synergistic way to affect brain function (Abner and others
2016). Is it valid to model dementia etiology without taking into account these major chronic diseases with known
complex connections to brain function? Thoroughly characterizing donors will require considering not only
comorbidity but also issues beyond dementia-related history, including non–central nervous system systemic
health. To address this, an accepted framework or set of
guidelines developed by the research community, funding bodies, and regulators would vastly help in standardizing the information gathered per donor for the purposes
of disease modeling.
Although research attention has, understandably,
focused on genetic and environmental risk, and on diagnosis, the single biggest risk factor for all forms of
dementia is age. Induced pluripotent stem cells (iPSCs)

are thought to be the equivalent, in stage, to fetal cells; if
they are aged in the laboratory, is this the equivalent of
ageing in a person? Can organoids be used to study the
mechanisms by which ageing contributes to dementia?

Question 4: Just How Much of the
Risk of Alzheimer Dementia Is
Genetic and What Is the Role of
APOE4?
There are a very small number of families that are
affected by Mendelian younger-onset forms of AD
(YOAD, familial AD). Symptoms of dementia in YOAD
often begin between 40 and 50 years of age due to a
fully penetrant mutation in one of the APP, PSEN1, or
PSEN2 genes (Goate and others 1991; Levy-Lahad and
others 1995; Sherrington and others 1995). For these
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Table 1. Summary of Organoid Models Used in Alzheimer’s Disease Research.
Summary
The authors successfully recapitulated Alzheimer’s
disease pathology, including Aβ aggregates and
hyperphosphorylated tau in cerebral organoids. Choi and
colleagues (2014) showed that inhibition of Aβ generation
reduced Aβ pathology and tauopathy; glycogen synthase
kinase 3 regulated Aβ-mediated tau phosphorylation.
The 3D neuronal model generated recapitulated both tau
and amyloid pathology. β and γ-secretase inhibitors were
more efficient in reducing Aβ levels in 2D than in 3D
neuronal cultures and the response to drug treatment
was highly variable among the different iPSC lines.
Using iPSC-derived cerebral organoids AD
phenotypes were observed, including Aβ aggregates,
hyperphosphorylated tau, and endosome abnormalities.
Patient-derived organoids with β- and γ-secretase
inhibitors resulted in a significant reduction in Aβ and tau
pathology.
Cerebral organoids derived from YOAD and Down
syndrome (DS) patients spontaneously developed
structures reminiscent of Aβ plaques and NFTs over time.
These structures were not observed in iPSCs derived
from healthy controls, patients affected by CreutzfeldtJakob disease or mouse embryonic stem cells and iPSCs.
APOE4 cerebral organoids demonstrated accumulation of
Aβ and tau hyperphosphorylation after 6 months, whereas
fAD organoids used in Raja and others (2016) showed
pathology after 2 months. APOE4 alone was sufficient to
induce AD pathology. APOE4 in LOAD organoids had
significantly higher levels of Aβ after 6 months compared
to age-matched APOE3 organoids. These findings provide
evidence for the role of APOE4 in sAD; gene editing to
APOE3 protected against AD pathology.
This study generated a novel 3D triculture system
using a microfluidic platform for neurons, astrocytes,
and microglia. There was increased Aβ, inflammatory
cytokines, chemokines and hyperphosphorylated tau
in the triculture system. The model showed microglial
recruitment and neurotoxic properties, including proinflammatory cytokine/chemokine release, axonal damage
and nitric oxide release, which was proposed to damage
neurons and astrocytes in culture. Knocking down Tolllike receptor 4 (TLR4) protected against neuronal and
astrocyte loss. The iPSC derived triculture replicated
microglial recruitment and activation and neuronal and
astrocyte loss.
Aβ secretion and accumulation was promoted by the
chemical inducer Attin-5, which increased Aβ42 and Aβ42/
Aβ40 ratio.

Cell Line

Days Matured

Reference

ReN cell VM
overexpressing
human APP and PSEN1
containing YOAD
mutations

42–84 days

Choi and others
(2014)

iPSCs derived from
PBMCs of five LOAD
patients

42–63 days

Lee and others
(2016)

iPSCs derived from four
YOAD patients with
APP duplication or
PSEN1 mutation

60–100 days

Raja and others
(2016)

iPSCs derived from a
YOAD patient with a
mutation in PSEN1 and
a DS patient

30–110 days

Gonzalez and
others (2018)

iPSC line derived from
LOAD patient and
healthy control.
Used CRISPR/Cas9
to convert APOE4 to
APOE3 or vice versa.

180 days

Lin and others
(2018)

ReN cell VM expressing
APP containing YOAD
mutations with
both K670N/M671L
(Swedish) and V717I
(London), human
microglia SV40 cell
line, and SCR131 iPSC
neural progenitors

21–70 days

Park and others
(2018)

iPSCs reprogrammed
from CRL-2522
fibroblasts

60–225 days

Pavoni and
others (2018)

Aβ = amyloid-β; DS = Down syndrome; LOAD = late-onset Alzheimer Dementia iPSCs = induced pluripotent stem cells; NFTs = neurofibrillary
tangles; PBMCs = peripheral blood mononuclear cells; YOAD = younger-onset Alzheimer Dementi.

families, the risk is genetic. However, the great majority
of cases of Alzheimer dementia are late-onset (LOAD;
>65 years of age), not Mendelian (although the disease
“runs in families”), and influenced by more common
genetic variants, notably those within the apolipoprotein

E (APOE) gene (Strittmatter and others 1993) but also
other genes (Fig. 3). The term “sporadic” is a misnomer;
Alzheimer dementia is not sporadic, even if we do not
yet understand all of the predetermining genetic and
environmental risk factors.
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Figure 3. Genetic risk for Alzheimer’s disease. Mutations in APP, PSEN1, and PSEN2 that cause younger-onset AD (YOAD; also
known as “familial AD”) are rare with the vast majority of genetic risk for late onset (LOAD; also known as “sporadic AD”)
arising through common variants in multiple genes that each increase risk but which individually are not causative. Figure modified
from Karch and Goate (2015).

The importance of APOE4 has been known for more
than 25 years (Qian and others 2017; Spinney 2014).
Approximately 25% of the population has one copy of
APOE4, and approximately 2% is homozygous for this
variant, but both APOE4 prevalence and its impact vary
somewhat for different ethnic groups (Rajabli and others
2018). Possession of one allele of APOE4 increases risk
of developing AD threefold, while two copies of APOE4
increases risk 15-fold, matching a co-dominant model.
Healthy, non-AD adults with high levels of amyloid show
higher levels of memory decline if they are APOE4 carriers (Lim and others 2016; Thai and others 2015).
Although APOE4 is the major genetic determinant for
developing LOAD, around half of those with an APOE4
allele will not develop dementia (Qian and others 2017).
The impact of risk factor genes beyond APOE therefore
needs to be considered. This has led to development of a
polygenic risk score, which takes into account the contributions of alleles of many genes, each with a small effect
contributing to the risk of developing LOAD (EscottPrice and others 2015). Some of the “minor risk genes”
describe functions specific to neurons, such as synaptic
processes and axonal transport, while others affect pathways in lipid metabolism and inflammation (Lambert and
others 2013).
It is important to note that, unlike the Mendelian
autosomal dominant mutations, APOE4 is a risk factor
and is not fully penetrant. While it is usually assumed
that this involves interactions with other genetic variants, it is still possible that genetics and lifestyle

interact to lower or increase AD risk. The ethical issues
regarding privacy, consent, data sharing, and risk of reidentification associated with acquiring a full genetic
profile from individuals can be a barrier to stem cell–
based studies. However, stem cell studies of dementia
would be improved by knowledge of the full genetic
profile of each donor; advanced molecular technologies, such as genome editing and single-cell RNA
sequencing, should assist in assigning specific cell
functions to particular combinations of risk variants.

Question 5: Are Protein Aggregates
the Main Culprit?
The amyloid hypothesis (Hardy and Higgins 1992) was
the first attempt to explain the relationship between the
key pathological features of AD (beta-amyloid [Aβ]
plaques and tau neurofibrillary tangles) and the development of dementia. It argues for a central role for Aβ as the
trigger for the key features of AD. It is based on three
major findings: (1) that mutations in the amyloid precursor protein (APP) gene itself, and in pathways associated
with Aβ production, cause familial YOAD; (2) that there
is a large amount of Aβ found in the brains of affected
individuals; and (3) that persons with Down syndrome,
who synthesize higher amounts of Aβ as the gene for Aβ
is on chromosome 21, develop YOAD.
Although amyloid is important in AD, there is a growing view that the amyloid hypothesis is not complete
(Makin 2018). Amyloid load does not correlate closely
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Figure 4. Summary of the amyloid, tau, and inflammation hypotheses for Alzheimer’s disease. Amyloid precursor protein
(APP) is a membrane protein that is proteolyticaly cleaved by multiple enzymes. The non-amyloidgenic pathway proceeds
when APP is cleaved by the activity of α-secretase (α-sec) to soluble APP α (sAPPα) and APP carboxy terminal fragment α
(APP-CTFα), these products are cleaved by γ-secretase (γ-sec) to produce truncated Aβ (p3) and the cytoplasmic polypeptide
named AICD. The amyloidgenic pathway occurs when APP undergoes cleavage by β-secretase (β-sec) to form sAPPβ and
APP-CTFβ. These proteins are cleaved by γ-sec to form AICD and amyloid-β (Aβ). In YOAD, mutations in APP, PSEN1, and
PSEN2 there is an increase in the 42-residue Aβ42, relative to Aβ40, which leads to an increase in Aβ oligomers and amyloid
plaque formation (Thinakaran and Koo 2008). Tau binds to microtubules and is important in cytoskeletal function. In AD, tau
is hyperphosphorylated resulting in cytoskeletal dysfunction. Hyperphosphorylated tau detaches from microtubules and forms
paired helical filaments that aggregate and form neurofibrillary tangles (NFTs). Inflammation is hypothesized to contribute to
cognitive loss in AD. Astrocytes and microglia are activated in the AD brain, releasing pro-inflammatory cytokines (e.g., tumor
necrosis factor-α [TNFα], interleukin [IL]-1β, IL-6, interferon-γ [IFNγ]) and chemokines (e.g., MIP-1α and MIP-1β) resulting in
neuronal death, either by directly damaging neurons or by failing in their normal function to clear aggregates from the brain (Azizi
and others 2015). There are multiple underlying molecular pathways leading to AD; intersecting pathways between amyloid, tau,
inflammation, and other processes contribute to a complex mechanism that drives neurodegeneration.

with cognitive loss (Hedden and others 2013), and recent
trials that successfully removed amyloid from the brains
of those with Alzheimer dementia did not have an impact
on clinical progression (Wang and others 2017).
Two alternative explanations for the cause of AD
focus, respectively, on the role of tau, or inflammation
(Figure 4). Tau pathology occurs during ageing, starting in the lateral entorhinal cortex (Braak and others
2011). It is possible that amyloid catalyzes the spread
of tau rather than directly inducing tau pathology. This
model could potentially explain the “no going back”
theory: once tau deposition is initiated, removing amyloid would not be effective at stopping AD progression

(Jacobs and others 2018; Price and Morris 1999). A
range of methods have been used to assess Aβ and tau
“pathology” in cerebral organoids from AD patients
and controls (Figure 5).
The suggestion that inflammation is a driver of cognitive loss is supported by data demonstrating key roles for
immune cells in controlling relevant normal brain function (Szepesi and others 2018). Many of the minor genes
implicated in AD are associated with microglial or
immune cell function, whether through modulation of
inflammation or regulating non-inflammatory processes,
such as synapse loss (Hong and others 2016a; Hong and
others 2016b; Kinney and others 2018).
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Figure 5. Assessing Aβ and tau pathology in human brain organoids. (A) The localization of Aβ and phosphorylated tau (p-tau)
has been visualized in organoids by immunocytochemistry (Choi and others 2014; Gonzalez and others 2018; Lee and others
2016; Lin and others 2018; Park and others 2018; Pavoni and others 2018; Raja and others 2016). (B) β-sheet aggregates have
been stained with the fluorescent Thioflavin-S (Thio S) dye. Thio S staining was proposed to identify tau pathology in AD
organoids (Raja and others 2016), though the precise molecular identity of the aggregates needs to be confirmed. (C) Enzymelinked immunosorbent assays (ELISAs) have been used to quantify secreted Aβ in the organoid medium (Choi and others 2014;
Gonzalez and others 2018; Lee and others 2016; Lin and others 2018; Park and others 2018; Pavoni and others 2018; Raja
and others 2016). (D) Protein levels of Aβ and p-tau have been compared in AD and control organoids by western blotting
semiquantitative analysis (Choi and others 2014; Gonzalez and others 2018; Lin and others 2018; Park and others 2018; Raja and
others 2016). See also Table 1.

Twenty-five years after it was first proposed, the amyloid hypothesis remains hotly debated, with many voices
arguing for the need for new ideas (Makin 2018).
However, there is no need to assume that there is only one
player in the underlying molecular pathways leading to
AD. Amyloid, tau, and inflammation (and other processes) are best seen as interacting parts in a complex
process that leads to dementia.
Rarer diseases than AD that are characterized by
aggregates of proteins other than amyloid can lead to
neurodegeneration in the absence of amyloid plaques
(non-Alzheimer dementias), such as tau aggregation in

age-related tauopathy, progressive supranuclear palsy,
or dementia with Lewy bodies and TDP-43 aggregation in hippocampal sclerosis or frontotemporal lobar
dementia (Nelson and others 2016). TDP-43 pathology
biomarkers are unreliable (Steinacker and others
2019), while tau imaging tools remain problematic in
terms of off-target (non-tau) binding and a reduced
ability to identify non-AD tau aggregation (Leuzy and
others 2019). Developing reliable biomarkers is important for accurate disease models and to understand the
link between aggregation of certain proteins and
dementia.

Ooi et al.

Question 6: How Reproducible Are
the Data Generated from iPSCs?
If cerebral organoids are to be used as research workhorses in the study of dementia, there is an implicit
assumption that they can be prepared with a high degree
of replicability. However, there are still many questions
about whether different stem cell lines, and the organoids
made from them, are sufficiently identical to allow comparisons to be made between them.
Many groups have generated patient-specific iPSC
lines carrying mutations in the genes PSEN1, PSEN2,
and APP (Arber and others 2017). While iPSC lines
show some phenotype expression associated with AD
after differentiation to brain organoids, iPSC line variability is an issue when identifying potential phenotypes.
Functional variation between iPSC lines and clones
relate to their capacity to differentiate to a particular
germ layer or cell identity. These functional differences
are underpinned by variation at the transcriptional and
epigenetic levels, which may be due to genetic variation,
level of reprogramming, copy number changes during
reprogramming, parental cell origin, and/or culture conditions (Ortmann and Vallier 2017; Polo and others 2010;
Popp and others 2018; Schwartzentruber and others
2018; Stadtfeld and others 2010).
Genome editing using homology-directed repair techniques, such as CRISPR/Cas9 is a powerful tool for disease modelling. The use of precise genome editing can
provide parallel cell lines that are genetically identical
across the genome and differ only for a single diseasecausing or disease-relevant mutation. The ability to compare gene-edited isogenic iPSC lines enables the
investigation of molecular and cellular differences and
strengthens tools for reverse genetic screening in iPSC
disease models, increasing the likelihood that definitive
disease profiles can be uncovered.
Because variation between and within iPSC lines is
exceptionally important, and indeed imposes a limit on the
generalizability of findings, there is great value in groups
sharing the same lines experimentally, and comparing
data for these lines both for similar and different experiments. In essence, this is a test of our commitment to open
science and collaboration. It is promising that initiatives
are proposed to facilitate sharing iPSC lines from patients
with different Mendelian forms of YOAD (Karch and others 2018).
It is also important to consider the extent to which cellular heterogeneity occurs during and after iPSC differentiation, even when using “robust” differentiation protocols.
Variation is observed both within one laboratory and
between laboratories while using the same iPSC lines and
following precisely the same differentiation protocols
(Schwartzentruber and others 2018; Volpato and others
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2018). This highlights the need for comprehensive genetic
and phenotypic analyses of differentiated iPSC-derived
cell types to compare results obtained between laboratories. When there is a conflict between data, whether within
a laboratory or between laboratories, this may reflect
authentic heterogeneity at the cellular level. Variability
between iPSC lines, iPSC clones, and their derivatives
shows that we need to treat data obtained with caution,
and go back to the “whole person” for true validation of
findings. This is not a simple task but it may be critical to
our understanding of disease; for example, for AD it is not
possible to truly confirm this diagnosis until the post mortem brain pathology can be confirmed (Perl 2010). In living patients amyloid imaging can be used as a biomarker
for amyloid levels (Klunk 2011) but this is costly and not
widely available (Vandenberghe and others 2013) and, as
a result, is often not performed prior to inclusion of patient
samples in stem cell studies.

Question 7: What about the
Environment? Can We Model
Modifiable Risk and Protective
Factors for AD?
We frequently see the statement that about a third of the
worldwide burden of dementia is attributable to modifiable
risk factors in the environment (Livingston and others 2017;
Norton and others 2014). It is therefore interesting to consider whether organoids might offer a model to investigate
these phenomena. This would be of value for it is not clear
whether such epidemiologic estimates arise from mixing
different forms of dementia together (in particular, VD and
AD), or are due to the inherent promiscuity of the aged
brain, pathologically speaking.
To model a complex protective factor would require
that: (1) organoids develop a bona fide pathological phenotype (i.e., for AD, amyloidosis + tauopathy + neurodegeneration) and (2) a readout of global organoid “neuronal
functionality” is possible.
To take a popular example, several studies suggest
exercise may attenuate the rate of cognitive decline in at
risk elders. Processes implicated include structural plasticity in the hippocampus, upregulation of systemic brainderived neurotrophic factor, functional brain network
change, and peripheral changes in immune-related cytokines and myokines (Kivipelto and others 2018; Larson
and others 2006; McEwen and others 2018; Muller and
others 2017). Other studies dispute the beneficial effect
of exercise on cognition (Young and others 2015).
Disentangling the impact of exercise on dementia using
human organoids, combining mechanical, biochemical,
and genomic approaches, represents the precision medical science we hope to achieve.
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More ambitiously, to address the role of education as a
protective factor for dementia, the “cognitive capacity”
of an organoid could be estimated by its ability to habituate to a stimulus or even encode a stimulus pattern (i.e.,
learn) and then retain it over an interstimulus interval
(i.e., memory)—ideas elaborated on in the next section.
This represents a transition from the study of organoid
structure to the study of organoid function.
Perhaps more attainable are models related to high
prevalence risk factors. Smoking is the strongest environmental toxin for dementia, responsible for an estimated 4.7
million cases in 2010 (Norton and others 2014). As a first
exploratory step, it would be interesting to model different
levels of tobacco smoke concentration in an incubator,
studying the effect on organoids for each type of dementia
(AD, VD, DLB, and FTLD). Another group of candidate
risk factors are metabolic: hypertension, type 2 diabetes,
and obesity (Clark and others 2018; Gabin and others
2017; Kivipelto and others 2018; Klimova and others
2018; Pegueroles and others 2018). It may be possible to
study neuronal and glial responses to aberrant metabolism
by exposing organoids to varying levels of glucose and/or
lipids. Other proposed environmental risk factors for
developing AD include microbial infections, such as herpes simplex (Fulöp and others 2018; Lin and others 1996).
Introducing an immune-related environment in organoids,
by the use either of microglia or of macrophages, together
with viral or bacterial pathogens, may allow the study of
whether herpes simplex contributes to AD pathology.
Another potential insult to the brain is ischemia and
hypoxia. There is a rich literature linking ischemia,
hypoxia, and sleep disorders to AD pathology, offering
circumstantial evidence (Valenzuela and others 2012).
While the long-term objective is to create vascularized
organoids perfusable with oxygen at different dissolved
tensions, hypoxia could be modelled in a simple fashion
by controlling atmospheric oxygen fraction over cultures.
Low oxygen environments are known to affect neural
stem cell proliferation, differentiation, and maturation
(Xie and Lowry 2018). Whether the same holds for complex multicellular organoids is a novel question, and any
impact on the development of AD pathology is unknown.

Question 8: Can We Measure
Cognition, and “Cognitive Reserve,”
in Organoids?
Memory loss and cognitive decline are the mainstays of a
clinical dementia diagnosis, often without data on the
presence of neurodegenerative pathology. Studies on
cognitive abilities show that early deposition of amyloid
is related to worse cognitive and memory performance,
even before individuals meet the clinical criteria for
dementia (Rodrigue and others 2012). Given that
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amyloid load does not directly correlate with symptoms
(Hedden and others 2013) it is not clear whether this is
the direct result of amyloid itself or an indirect effect of
other cell biological and degenerative processes. The biological processes underlying such cognitive impairment
are manifold, and most often include loss of connections
between neurons (Dorostkar and others 2015). Such disarrayed communication breaks down the synchronized
activity of entire areas, with working memory function
quickly lost (Morrison and Baxter 2012). Being able to
study the biological mechanisms behind cognitive decline
is therefore essential for an in vitro dementia model.
While histological tools exist to assess neurodegeneration, synaptic dysfunction, or alterations in neuronal/glial
interactions, real value would come from gaining this
information from living tissue, with the advantages of
longitudinal interrogation.
There is clearly a growing need to develop technologies that can reliably measure neuronal functionality
within organoids. Functional assays, such as calcium
imaging (Fig. 6) or microelectrode arrays (Fig. 7) can be
used to measure neuronal activity and formation of synchronous neuronal networks, and have already been successfully applied to iPSC-derived organoids (Quadrato
and others 2017). An important challenging factor to consider is the time needed for neurons to mature and form
networks within the organoids, which may take several
months (Quadrato and others 2017). It is not currently
clear how the organoids “age” or “mature” over time, in
terms of their functional activity. This process needs to be
characterized so that we can understand whether changes
in functional outputs are disease related or an artefact of
chronic long-term culture conditions. Other complimentary approaches may be to optically measure calcium
transients or changes in membrane potentials within a
multitude of neurons in real time and across the whole
three-dimensional structure, or measuring neurotransmitter levels, such as glutamate, generated within the organoids (Nasr and others 2018; Sloan and others 2018). A
major challenge is to develop live imaging tools and electrical recording techniques that overcome the z-plane
depth limitation of organoid models. Another challenge is
to develop organoid-specific data analysis tools that
accurately model the structural and functional information that can be matched with clinical data.
On the flip side to memory loss and cognitive decline,
it would also be valuable to use organoids to model and
measure cognitive reserve—a concept often invoked to
explain the disconnect observed in ~30% of older persons
who express suprathreshold levels of AD pathology in
terms of amyloid deposition (whether at post mortem or
by in vivo imaging) but do not exhibit dementia (Stern
and others 2018). In essence, cognitive reserve refers to
the adaptability, efficiency, and flexibility of the brain
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Figure 6. Functional assessment of cerebral organoids by calcium imaging. (A) A representative image of a culture derived from
a YOAD cerebral organoid loaded with the ratiometric calcium indicator Fura2-AM. A 9-month-old organoid was seeded onto a
glass coverslip for Ca2+ imaging. The image shows the overlay of 340 nm and 380 nm channels; each colored circle corresponds
to a region of interest (ROI) represented in (B). When Ca2+ binds to the indicator, fluorescence at 340 nm increases, while 380
nm fluorescence decreases. The 340/380 ratio is thus used as a measurement of Ca2+ responses to drugs or agonists or to assess
spontaneous activity. (B) Relative change in fluorescence intensity over time of specific ROIs from (A) using Fura2-AM. Neurons can
be stimulated with chemicals that are perfused into the bath chamber and the Ca2+ responses recorded. The culture was exposed
to the excitatory neurotransmitter glutamate (20 µM; perfusion indicated by the horizontal black bar) to elicit a Ca2+ response,
followed by high K+ (60 mM; perfusion indicated by the horizontal black bar) to mimic membrane depolarization. Responses may be
fast or slow transient increases or prolonged increases that do no return to baseline within the timeframe of the experiment.

Figure 7. Electrophysiological assessment of cerebral
organoids by microelectrode arrays. (A) Organoids can be
seeded in well chambers (B) on top of regularly spaced arrays
of electrodes. (C) Organoids are electrically active; shown are
recordings from two different organoids at 25 kHz, whereby
spikes identify electrophysiological activity. The recordings
show a difference in spontaneous activity from the two
organoids, which can be quantified via various parameters,
such as spike amplitude and firing rate. Experiments can be
designed to compare organoid responses to chemical or
electrical stimulation and can provide information on neuronal
network dynamics and the formation of functional circuits.

and its cognitive processes in the face of stressors such
that overall function is maintained and protected (Stern
and others 2018). Determinants of greater cognitive
reserve include lifelong mental stimulation and challenge,
including education, occupational complexity, and intellectual leisure pursuits. Organoids may be useful in modelling such determinants by measuring neuronal firing
activity, particularly in synchronous neuronal networks,
in response to different levels of stimulation. Currently, it
is difficult to assess how measurements of function in
organoids scale up to measurements in whole brains.
A theoretical approach that could be used is the
Perturbational Complexity Index that was developed and
tested in healthy subjects and coma patients (Casali and
others 2013). The technique uses transcranial stimulation
to assess consciousness that is independent of sensory
processing. However, the issue of consciousness in brain
organoids leads to significant ethical implications (see
Question 10). At present there is no evidence from published studies that brain organoids exhibit consciousness,
and in fact, single cell analyses suggest brain organoids
show a lack of maturity (Bhaduri and others 2020).

Question 9: Can Organoids Be Used
for Drug Discovery?
There is a strong hope that organoids will be of immediate value for use in drug screening and development.
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Figure 8. Schematic showing opportunities for the use of brain organoids in the drug development pipeline. In particular, stem
cell–derived culture models have the potential to improve lead optimization for “formal preclinical” and clinical development.

However, while human brain organoids have potential to
model AD and other dementias, it is not yet clear whether
they can be adapted for applications in drug discovery.
The promise of organoids lies in their ability to model
complex processes and it is precisely this complexity
that is at odds with the industrial practice of targeted
drug discovery. Typically, drug screens adopt a reductionist approach, making use of simple, direct molecular
assays in the initial chemical screening phase to identify
active “hits” from libraries of chemical scaffolds.
Organoids are therefore unlikely to be useful at the initial
chemical library screening stage. Rather, they may come
into their own for identification of biochemical pathways
or specific molecules that modulate the course of disease, a research process often termed “target identification,” which precedes the commitment to a targeted drug
discovery campaign (Fig. 8).
Organoids will also have important roles to play in
selection of the most biologically active compounds in
the later stages of lead development, when more costly,
complex, and informative biological models are justifiable and valuable. Such models also have the potential
to identify opportunities for repurposing approved
drugs, and ultimately provide the means to personalize
therapy by identifying drugs that are most effective at
reversing the pathology in organoids produced from
patient-derived iPSCs.
It is tempting to suggest that a complex disease
requires a complex model to identify useful hits, even
during the early stages of hit identification. Can the
potential of organoids be harnessed at this early stage,
prior to target identification, using a “phenotypic” screening process? This will depend on whether a disease-relevant assay (or combination of assays) is replicable (as
discussed above) and is sufficiently sensitive to measure
drug activity. Quantitative phenotypic screening assays

need to be devised that are specifically designed for
organoid cultures and address these issues, particularly in
relation to reproducibility.

Question 10: What Are the Ethical
Issues and Community Expectations
Around Brain Organoids?
When stem cells were first derived from human embryos
that had been stored for in vitro fertilization but were no
longer wanted for reproduction, there was a great deal of
ethical debate; some people with religious objections to
the destruction of embryos opposed the generation of
embryonic stem (ES) cells. However, most stem cell
research today is performed using iPSCs, which do not
raise the same level of ethical concern. Nevertheless,
human ES cells are still regarded as being the “gold standard” for potency, and the International Society for Stem
Cell Research has established guidelines for researchers,
clinicians, and funding agencies in this regard (Daley and
others 2016).
The fact that the specific issues around embryo
destruction have been solved by scientific advances does
not mean that there are no remaining ethical concerns
voiced by the community (Allum and others 2017;
Bredenoord and others 2017; Chalmers and others 2017;
Stadelmann and Torgler 2017; Shepherd 2018). Recent
discussions around the ethical issues of brain organoids
describe consciousness as a moral limit of brain organoid
research (Bayne and others 2020; Koplin and Savulescu
2019; Sawai and others 2019). While most people favor
the use of stem cells for medical research and clinical
care, they add a strong proviso: the public must be
involved in open and frank discussions around ethical
issues, such as privacy and consent, and the way organoids are derived and treated (Farahany and others 2018).
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It is difficult to obtain informed consent to collect,
study, and store biological material from people with
dementia, although a common sense approach combined
with information from people with early stages of
dementia indicate that many of them would wish to participate (Howe 2012; Slaughter and others 2007).
Because stem cell and organoid research is advancing
rapidly, it is not possible to predict all of the ways in
which cells might be used in future. The coalescence of
these two concerns raises complications for those using
organoids for dementia research, and it is imperative
that researchers engage with those living with dementia
and their families and carers (Pachana and others 2015;
Ries and others 2017). It may be possible to use a
research equivalent of an “advanced care directive,”
where a person consents to future research relevant to
dementia, prior to cognitive decline.
Since family history is a well-known risk factor, children of persons with AD will be a group of highly motivated individuals who wish to participate in research,
just as soon as there is hope of an effective intervention.
Because of this, and unlike many situations in medical
research, cell donors should be reidentifiable, particularly if they carry the major risk allele APOE4. This
leads to a range of ethical (and legal) issues around deidentifying data, sharing of data between research
groups (Isasi and others 2014), and whether there is a
responsibility to inform participants of their genetic risk
status (Milne and others 2018; Timmermans and
Buchbinder 2010). It is important to encourage research
into the effects of revealing high-risk genotypes to
asymptomatic adult children of people with AD, in the
context of availability of direct-to-consumer genotyping
(Green and others 2009).
The expectation of the community that they will be
consulted about research using stem cells also involves a
major commitment to education, both about dementia
and about stem cell science (King and others 2014). On
an issue as critical and costly as this, it may be appropriate for national research bodies, such as the National
Institutes of Health in the United States, the Medical
Research Council in the United Kingdom and the National
Health and Medical Research Council of Australia to play
a major role in initiating both community education and
public discussion on dementia.

Final Thoughts
Caveats and Challenges: Whilst organoids provide
opportunities for disease modelling, the current literature
suggests cell maturation remains limited due to high levels of cellular stress (Bhaduri and others 2020). Future
work needs to consider how to progress model systems to
better recapitulate the spatiotemporal dynamics of
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differentiation and how to deal with the impact of cellular
stress during long term cell culture. Addressing these difficulties is essential to improve our understanding of the
model systems and the diseases they represent.
Opportunities: Stem cells and organoid technology will
enable us to ask, and maybe even answer, some of the
fundamental questions about pathological processes and
risk associations for dementia, as well as neurodegenerative diseases more broadly (Lambert and others 2013).
The most direct route is for stem cell scientists and clinicians to work closely together, in a manner where the
technological advances and knowhow of scientists are
guided by the most perceptive clinical insights and the
most pressing health needs.
This approach has led to successes for other diseases.
Some serious diseases (such as measles and polio) have
been virtually eliminated, others (such as breast cancer or
HIV in many countries) are much less likely to kill and
are amenable to treatment, while conditions such as cardiovascular diseases (myocardial infarcts and strokes)
still are common, but have been displaced to occur more
often in the elderly. These transformational medical
advances, be they environmental, behavioral, or pharmacological, are based on research.
Many who have worked on diseases outside the brain
are surprised at how little we know about the fundamentals
of Alzheimer disease and other causes of dementia. We
eagerly await data showing whether pre-symptomatic
removal of amyloid from the brain delays the onset of
Alzheimer dementia, particularly if initiated prior to symptoms. At this stage, iPSC lines and cerebral organoids may
reflect some of the clinical features of the patients from
whom they were obtained, particularly with respect to
pathology and etiology. If this proves to be true and technical variation can be controlled, then cerebral organoids
may become a very powerful research tool for the study of
dementia. There is room for optimism, but also a need for
caution, with an assurance that rigorous and replicable
hypothesis-driven experiments can translate back to real
people with real-world clinical problems.
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